CD22 and B-cell non-Hodgkin lymphoma: For B‐cell NHL, the phase 1/2 NCT00299494 trial investigated the efficacy of INO plus rituximab for R/R CD20/CD22‐positive B‐cell NHL patients; the ORR was 87% and 74%, and the 2‐year PFS rates were 68% and 42% for follicular lymphoma (FL) and DLBCL, respectively.88